Thursday, June 26, 2025 6/26/2025

PHASE 2 STUDY OF HIGH DOSE DHA FOR THE TREATMENT OF X-LINKED RETINITIS PIGMENTOSA

Award Number: R01FD002543
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2005
PERIOD OF PERFORMANCE END DATE: 02/28/2014

Group Awards By:

View Award Description

PHASE 2 STUDY OF HIGH DOSE DHA FOR THE TREATMENT OF X-LINKED RETINITIS PIGMENTOSA - DESCRIPTION (provided by applicant): The purpose of this grant application is to complete a placebo-controlled, randomized, Phase 2 clinical trial to test the hypothesis that dietary supplementation with a high dose of the long-chain omega-3 polyunsaturated fatty acid DHA is beneficial in retarding the progressive retinal degeneration and associated loss of visual function in patients with XLRP. XLRP is one of the most severe forms of hereditary retinal degeneration with an onset in early childhood and is characterized by night-blindness, decreased acuity, and tunnel vision/legal blindness due to a very slow degeneration of rod and cone photoreceptors. There is no cure for XLRP and treatment of symptoms is limited. Although the disease has distinct genetic origins, nutrition may ultimately influence the rate of progression. The high level (greater than 30%) of DHA in photoreceptors is suggestive of a role in maintaining the integrity of retinal membranes surrounding the enzymes responsible for phototransduction. From previous results, a high dose of dietary DHA based on bodyweight should sufficiently elevate blood DHA in patients with early stage XLRP (ages 7 to 32 years) to a level estimated to slow the loss of cone photoreceptor function. Capsule intake is 30 milligrams DHA/kilogram/day so as to target a red blood cell (RBC)-DHA level of roughly 12 to13% of total fatty acids. Annual vision tests are: full-field cone electroretinographic (ERG) responses to 31-Hertz flicker as the primary functional outcome, rod ERGs, a-wave rod and cone ERG photoreceptor assessment, visual acuity, visual fields, fundus photography, dark-adapted thresholds, ocular coherence tomography (OCT) and comprehensive eye exams. Blood DHA analysis (every 6 months) and biosafety measures (annually) assess RBC fatty acids, platelet aggregation, plasma vitamins A and E, plasma antioxidant capacity, plasma malonyldialdehyde, plasma oxidized low-density lipoprotein (LDL), lipoprotein lipids, and comprehensive metabolic blood chemistry. The rarity of this disease resulted in a prolongation of the recruitment period. The first of the 55 active participants enrolled beginning on August 1, 2005, and last enrolled June 6, 2008. Thus, completion of the 4-year intervention supplement ended August 1, 2009 for the first enrollee and will end June 15, 2012 for the last. This application proposes to extend supplementation and annual testing of the participants beyond 4 years as we will not be able to disclose group assignments until June 2012. The additional data collected will be used in ancillary data analysis to evaluate longer term efficacy of the DHA intervention. As of January 31, 2010, 3 participants are in their second year of supplementation, 18 in their third year, 21 in their fourth year and 13 have begun their fifth year on the trial. With a sample size of 55 active participants, 24 subjects per group (placebo and DHA-supplemented) have remained to attain statistical significance in this 4-year trial. Based on Phase 1 clinical trial results, a high dose of dietary DHA shows promise in retarding progression of this blinding eye disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2013 ( Subtotal = $21,976 )
2013	2013	RETINA FOUNDATION OF THE SOUTHWEST	9900 N CENTRAL EXPRESSWAY #400	DALLAS	TX	75231	DALLAS	USA	Food and Drug Administration Research	001	8	9/12/2013	SUPPLEMENT FOR EXPANSION	$21,976
2013	2012	RETINA FOUNDATION OF THE SOUTHWEST	9900 N CENTRAL EXPRESSWAY #400	DALLAS	TX	75231	DALLAS	USA	Food and Drug Administration Research	000	8	2/21/2013	NON-COMPETING CONTINUATION	$0
														Subtotal = $21,976

Issue Date FY: 2012 ( Subtotal = $362,482 )
2012	2012	RETINA FOUNDATION OF THE SOUTHWEST	9900 N CENTRAL EXPRESSWAY #400	DALLAS	TX	75231	DALLAS	USA	Food and Drug Administration Research	000	8	2/15/2012	NON-COMPETING CONTINUATION	$362,482
														Subtotal = $362,482

Issue Date FY: 2011 ( Subtotal = $398,482 )
2011	2011	RETINA FOUNDATION OF THE SOUTHWEST	9900 N CENTRAL EXPRESSWAY #400	DALLAS	TX	75231	DALLAS	USA	Food and Drug Administration Research	000	7	4/7/2011	COMPETING CONTINUATION	$398,482
2011	2010	RETINA FOUNDATION OF THE SOUTHWEST	9900 N CENTRAL EXPRESSWAY #400	DALLAS	TX	75231	DALLAS	USA	Food and Drug Administration Research	001	6	4/7/2011	NON-COMPETING CONTINUATION	$0
														Subtotal = $398,482

Issue Date FY: 2010 ( Subtotal = $347,672 )
2010	2010	RETINA FOUNDATION OF THE SOUTHWEST	9900 N CENTRAL EXPRESSWAY #400	DALLAS	TX	75231	DALLAS	USA	Food and Drug Administration Research	000	6	3/17/2010	NON-COMPETING CONTINUATION	$347,672
														Subtotal = $347,672

Issue Date FY: 2009 ( Subtotal = $347,926 )
2009	2009	RETINA FOUNDATION OF THE SOUTHWEST	9900 N CENTRAL EXPRESSWAY #400	DALLAS	TX	75231	DALLAS	USA	Food and Drug Administration Research	000	5	3/2/2009	NON-COMPETING CONTINUATION	$347,926
														Subtotal = $347,926

Issue Date FY: 2008 ( Subtotal = $405,914 )
2008	2008	RETINA FOUNDATION OF THE SOUTHWEST	9900 N CENTRAL EXPRESSWAY #400	DALLAS	TX	75231	DALLAS	USA	Food and Drug Administration Research	000	4	3/4/2008	COMPETING CONTINUATION	$405,914
														Subtotal = $405,914

Issue Date FY: 2007 ( Subtotal = $59,472 )
2007	2007	RETINA FOUNDATION OF THE SOUTHWEST	9900 N CENTRAL EXPRESSWAY #400	DALLAS	TX	75231	DALLAS	USA	Food and Drug Administration Research	001	3	9/20/2007	SUPPLEMENT FOR EXPANSION	$59,472
														Subtotal = $59,472

Grand Total All Awards = $1,943,924

Top

All Categories

About

Search

Reports

Data Submission

Award Information

PHASE 2 STUDY OF HIGH DOSE DHA FOR THE TREATMENT OF X-LINKED RETINITIS PIGMENTOSA

Award Number: R01FD002543

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2005

PERIOD OF PERFORMANCE END DATE: 02/28/2014

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer